Colombia fines Pfizer $25K for drug price inflation

Alia Paavola - Print  | 

A regulatory agency in Colombia has fined Pfizer nearly $25,000 for selling its medications above the maximum prices set by authorities, according to STAT.

The anticompetitive regulator, Superintendency of Industry and Commerce, claims Pfizer sold several of its medicines at a price ranging from 4 percent to 651 percent above the agreed-upon amount between July 2016 and December 2016.

The agency claims that Pfizer sold its ophthalmic solution Xalatan for about $33 a unit, when the agency set the price at $4. Additionally, Pfizer's antidepressant Effexor was sold 348 percent above the official price, according to the regulators. 

A Pfizer spokesperson denied the allegations and told STAT the company was complying with the regulator's investigation. 

The move comes as a growing number of countries worldwide are attempting to curb the rising costs of prescription drugs. 

Access the full report here. 

More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Average chief pharmacy officer salary by state

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.